Fri. Mar 29th, 2024

Biocon’s subsidiary company Biocon Biologics got approval from the Drugs Controller General of India (DCGI) for its new device CytoSorb invented to treat critical Covid-19 Patients. CytoSorb functions as a blood purifier and can be substantial in the treatment of Covid-19 Patients.

According to a Press Release of Company, the device is designed for extracorporeal blood purification (EBP) which will help in reducing pro-inflammatory cytokines levels in Patients confirmed with Covid-19 infection who have been admitted to the intensive care unit with confirmed or imminent respiratory failure. Previously, CytoSorb was approved in April by the United States Food and Drug Administration for emergency use.

The company said, “Biocon Biologics has been granted a licence for emergency use of CytoSorb in the public interest by the Indian health regulator to treat coronavirus patients who are 18 years of age or older. The licence will be effective until control of the Covid-19 outbreak in the country”. According to studies, serious patients of Covid-19 experience ‘Cytokine Storm’ or ‘Cytokine Release Syndrome’ (CRS) that leads to excessive inflammation, organ failure and death. CytoSorb may help to mitigate or prevent this injury by reducing Cytokine Storm and deadly inflammatory response by purifying blood.

Biocon’s Executive Chairperson, Kiran Mazumdar-Shaw said, “CytoSorb was introduced by Biocon in India in 2013. Since then many patients undergoing organ transplant and sepsis treatment have benefitted from it. DCGI approval for emergency use of CytoSorb for critical COVID-19 patients is an important example of how industry and regulators are working in tandem to urgently provide physicians and patients with new treatment options in the fight against Covid-19”.

Leave a Reply

Your email address will not be published. Required fields are marked *